Business Description
Vivoryon Therapeutics NV
ISIN : NL00150002Q7
Total Employee Number:
16Compare
Compare
Traded in other countries / regions
VVY.Netherlands05Y.GermanyVVYN.Austria0R3M.UK IPO Date
2014-10-27Description
Vivoryon Therapeutics NV is a clinical-stage biopharmaceutical company focused on discovering, developing, and potentially commercializing small-molecule-based medicines that modulate the activity and stability of pathologically altered proteins. Vivoryon is currently focused on developing treatments for chronic kidney disease (CKD), and more precisely, is initially targeting stage 3b and worse diabetic kidney disease (DKD). Its product pipeline includes various drug candidates, including varoglutamstat (PQ912), VY2149, and NCE, as potential treatments for chronic kidney disease (CKD), and more precisely, are initially targeting stage 3b and worse diabetic kidney disease (DKD). The company is also pursuing antibody-based approaches for Alzheimer's disease.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 52.22 | |||||
Equity-to-Asset | 0.63 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.01 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 36.9 | |||||
3-Year EPS without NRI Growth Rate | 36.4 | |||||
3-Year FCF Growth Rate | 31.8 | |||||
3-Year Book Growth Rate | -47.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -14.43 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 37.91 | |||||
9-Day RSI | 45.75 | |||||
14-Day RSI | 47.77 | |||||
3-1 Month Momentum % | -18.22 | |||||
6-1 Month Momentum % | -29.03 | |||||
12-1 Month Momentum % | -22.86 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 7.68 | |||||
Quick Ratio | 7.68 | |||||
Cash Ratio | 6.74 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -7.1 | |||||
Shareholder Yield % | -14.86 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -168.22 | |||||
ROA % | -105.31 | |||||
ROIC % | -602.71 | |||||
3-Year ROIIC % | -4817.29 | |||||
ROC (Joel Greenblatt) % | -7864.29 | |||||
ROCE % | -121.85 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 7.25 | |||||
Price-to-Tangible-Book | 8.92 | |||||
EV-to-EBIT | -3.27 | |||||
EV-to-EBITDA | -3.33 | |||||
EV-to-Forward-EBITDA | 56.21 | |||||
EV-to-Forward-Revenue | 8.35 | |||||
EV-to-FCF | -3.41 | |||||
| Price-to-Net-Current-Asset-Value | 9.67 | |||||
| Price-to-Net-Cash | 11.6 | |||||
Earnings Yield (Greenblatt) % | -30.58 | |||||
FCF Yield % | -24.63 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Vivoryon Therapeutics NV Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.33 | ||
| Beta | 1.1166 | ||
| 3-Year Sharpe Ratio | 0.2 | ||
| 3-Year Sortino Ratio | 0.54 | ||
| Volatility % | 31.04 | ||
| 14-Day RSI | 47.77 | ||
| 14-Day ATR (€) | 0.077099 | ||
| 20-Day SMA (€) | 1.15575 | ||
| 12-1 Month Momentum % | -22.86 | ||
| 52-Week Range (€) | 1 - 1.84 | ||
| Shares Outstanding (Mil) | 29.61 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Vivoryon Therapeutics NV Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Vivoryon Therapeutics NV Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-12-04 09:00 | In 139 days | ||
| Third quarter earnings results for 2026 | 2026-12-04 | In 138 days | ||
| Second quarter earnings conference call for 2026 | 2026-09-04 15:00 | In 48 days | ||
| Second quarter earnings results for 2026 | 2026-09-04 | In 47 days | ||
| General meeting for 2026 | 2026-07-22 | In 3 days | ||
| First quarter earnings conference call for 2026 | 2026-06-11 | 1.20 (+1.69%) | ||
| First quarter earnings results for 2026 | 2026-06-11 | 1.20 (+1.69%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-04-23 09:00 | 1.34 (-0.37%) | ||
| Annual report for 2025 | 2026-04-23 | 1.34 (-0.37%) | ||
| Fourth quarter earnings results for 2025 | 2026-04-23 | 1.34 (-0.37%) |
Show
Entries
Vivoryon Therapeutics NV Frequently Asked Questions
What is Vivoryon Therapeutics NV(XAMS:VVY)'s stock price today?
The current price of XAMS:VVY is €1.16. The 52 week high of XAMS:VVY is €1.84 and 52 week low is €1.00.
When is next earnings date of Vivoryon Therapeutics NV(XAMS:VVY)?
The next earnings date of Vivoryon Therapeutics NV(XAMS:VVY) is 2026-09-04 Est..
Does Vivoryon Therapeutics NV(XAMS:VVY) pay dividends? If so, how much?
Vivoryon Therapeutics NV(XAMS:VVY) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Vivoryon Therapeutics NV
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers